Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Clinical trial NCT01772797 · COMPLETED

Trial details

NCT number: NCT01772797
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Anaplastic Lymphoma Kinase (ALK)Non-small Cell Lung Cancer

Start date: 2013-06-01
Primary completion: 2016-01-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.